Avalo Therapeutics, Inc.
AVTXHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Avalo Therapeutics, Inc. (AVTX) is listed under Biotechnology. At a $1.02B market cap, Avalo Therapeutics, Inc. ranks as a small-cap company within healthcare. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Market Cap
$1.02B
Beta
0.79
P/E (TTM)
—
P/E (Fwd)
-7.01
EPS (TTM)
$-5.57
EPS (Fwd)
$-2.76
ROE
-88.8%
ROA
-41.5%
Cash
$82.0M
Total Debt
$328,000
Free CF
-$23.2M
52W Change
209.9%
Annual Financials
Cash vs Debt
Avalo Therapeutics, Inc. holds $82.0M in cash against $328K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$23.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -88.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $18.1M (2022) to $59K (2025), a 100% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Avalo Therapeutics, Inc. and its sector.